RxDoctor Payments Data

George Lynskey, MD

Vascular & Interventional Radiology · Oxon Hill, MDNPI 1336391416

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 58.6% of the total. Reporting peaked in 2023 at $13,082 and has fallen 52.2% since, to $6,259 in 2025.

$22,234in general payments, 2019–2025

Across 85 payments — averaging $261.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$13K
  • Sirtex Medical Inc$6K
  • W. L. Gore & Associates, Inc.$740
  • Boston Scientific$497
  • Angiodynamics, Inc.$239
  • Inari Medical, Inc.$176
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$12,42556%
  • Speaking & faculty fees$6,00027%
  • Travel & lodging$1,0335%
  • Food & beverage$2,77612%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,234 in reported general payments places this provider in the 85th percentile of 75 vascular & interventional radiology providers in Maryland.

See all vascular & interventional radiology providers in Maryland

Medicare billing

Part B allowed, 2024
$707,220
Medicare patients
164
Services billed
2,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate34$309

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in Oxon Hill

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →